ReviewBritish journal of cancer1995
The genetics of breast and ovarian cancer.
Review in British journal of cancer, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 270 citations in OpenAlex.
- The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.BioMed research international · 2016Pooled it
- Screening for ovarian cancer: recommendation statement.Annals of family medicineGuideline
- Article
- Associations of the COVID-19 burden and various comorbidities of different ethnic groups in Israel: a cross-sectional study.Clinical and experimental medicine · 2023Article
- A Narrative Review of Breastfeeding and Its Correlation With Breast Cancer: Current Understanding and Outcomes.Cureus · 2023Review
- The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status.Reproductive sciences (Thousand Oaks, Calif.) · 2023Article
- Association ofAfrican health sciences · 2022Article
- Effects of methylenetetrahydrofolate reductase single-nucleotide polymorphisms on breast, cervical, ovarian, and endometrial cancer susceptibilities.Chronic diseases and translational medicine · 2021Article
- Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.International journal of molecular sciences · 2021Article
- Nutrigenomics and Breast Cancer: State-of-Art, Future Perspectives and Insights for Prevention.Nutrients · 2020Review
- MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature.Scientific reports · 2019Article
- Association ofFrontiers in endocrinology · 2019Article
- Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital.Journal of global oncology · 2018Article
- The Role of Knowledge on Genetic Counseling and Testing in Black Cancer Survivors at Increased Risk of Carrying a BRCA1/2 Mutation.Journal of genetic counseling · 2017Article
- Article
- Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.Journal of adolescent and young adult oncology · 2016Article
- Living With Genetic Vulnerability: a Life Course Perspective.Journal of genetic counseling · 2016Article
- Genomic Biomarkers for Breast Cancer Risk.Advances in experimental medicine and biology · 2016Review
- Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Article
- Large genomic rearrangement of BRCA1 and BRCA2 genes in familial breast cancer patients in Korea.Familial cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of genes are known to be involved in inherited susceptibility to breast and/or ovarian cancer. In the context of high-risk families the most important genes are BRCA1 on chromosome 17q, which is associated with a high penetrance of both breast and ovarian cancer, and BRCA2 on chromosome 13q, which causes a high risk of breast cancer but a lower risk of ovarian cancer. Other high-risk cancer genes that confer increased risks of breast or ovarian cancer in addition to other cancers include the hereditary non-polyposis colorectal cancer genes and the TP53 gene, which causes breast cancer as part of the Li-Fraumeni syndrome. The predisposing mutations in these genes are relatively rare in the population. More common genes which are associated with an increased, but lower, risk of breast cancer are the ataxiatelangiectasia gene and the HRAS1 gene. This paper reviews recent progress in mapping and cloning of these susceptibility genes, and provides estimates of the cancer risks associated with each gene and the frequency of predisposing mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.